These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 9876213

  • 1. Strategies that support declining cholinergic neurotransmission in Alzheimer's disease patients.
    Sirviö J.
    Gerontology; 1999; 45 Suppl 1():3-14. PubMed ID: 9876213
    [Abstract] [Full Text] [Related]

  • 2. The cholinergic hypothesis of Alzheimer's disease: a review of progress.
    Francis PT, Palmer AM, Snape M, Wilcock GK.
    J Neurol Neurosurg Psychiatry; 1999 Feb; 66(2):137-47. PubMed ID: 10071091
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Reappraising neurotransmitter-based strategies.
    Möller HJ.
    Eur Neuropsychopharmacol; 1999 Apr; 9 Suppl 2():S53-9. PubMed ID: 10332935
    [Abstract] [Full Text] [Related]

  • 7. [Acetylcholinesterase inhibitors for treatment of Alzheimer's disease].
    Shinagawa S, Shigeta M.
    Brain Nerve; 2014 May; 66(5):507-16. PubMed ID: 24807367
    [Abstract] [Full Text] [Related]

  • 8. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease.
    Levy ML, Cummings JL, Kahn-Rose R.
    Gerontology; 1999 May; 45 Suppl 1():15-22. PubMed ID: 9876214
    [Abstract] [Full Text] [Related]

  • 9. [Neurotransmitters in Alzheimer's disease].
    Manzano-Palomo S, De la Morena-Vicente MA, Barquero MS.
    Rev Neurol; 1999 May; 42(6):350-3. PubMed ID: 16575771
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: an update.
    Weinstock M.
    Neurodegeneration; 1995 Dec; 4(4):349-56. PubMed ID: 8846227
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical profile of donepezil in the treatment of Alzheimer's disease.
    Doody RS.
    Gerontology; 1999 Dec; 45 Suppl 1():23-32. PubMed ID: 9876215
    [Abstract] [Full Text] [Related]

  • 15. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
    Wenk GL.
    J Clin Psychiatry; 2006 Dec; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
    [Abstract] [Full Text] [Related]

  • 16. Effect of cholinesterase inhibitors on attention.
    Pepeu G, Giovannini MG, Bracco L.
    Chem Biol Interact; 2013 Mar 25; 203(1):361-4. PubMed ID: 23047023
    [Abstract] [Full Text] [Related]

  • 17. Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents.
    Lahiri DK, Rogers JT, Greig NH, Sambamurti K.
    Curr Pharm Des; 2004 Mar 25; 10(25):3111-9. PubMed ID: 15544501
    [Abstract] [Full Text] [Related]

  • 18. Do acetylcholinesterase inhibitors boost synaptic scaling in Alzheimer's disease?
    Small DH.
    Trends Neurosci; 2004 May 25; 27(5):245-9. PubMed ID: 15111005
    [Abstract] [Full Text] [Related]

  • 19. [Tacrine].
    Dávila C, Viteri C, de Castro P.
    Rev Med Univ Navarra; 1997 May 25; 41(1):58-64. PubMed ID: 9527715
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.